Goldman Sachs downgraded Ginkgo Bioworks to Sell from Neutral with a price target of $1.25, down from $3, which represents 26% downside from current levels....
In this edition of “Rising High,” The Fly conducted an exclusive interview with Rick Maturo, Director of Insights and Analytics at BDSA, a Colorado-based cannabis...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:Â Revance Therapeutics… To see the...
Shares of AbbVie (ABBV) are down $5.44, or 4%, to $132.52 in early trading after Coherus BioSciences (CHRS) announced that the company plans to launch...